PANDAS

What Is PANDAS?

PANDAS stands for Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections. It describes a subgroup of children who develop the abrupt onset of obsessive-compulsive symptoms, tics, or both, shortly after an infection with group A streptococcus — the bacterium responsible for strep throat and scarlet fever.

The central idea behind PANDAS is that the problem is not the bacterium itself but the immune response to it. In this model, antibodies produced to fight streptococcus mistakenly recognise proteins on cells in the brain, a process known as molecular mimicry. The result is an autoimmune disease that targets the brain rather than the throat, producing changes in mood, movement and behaviour rather than a sore throat alone.

PANDAS belongs to a wider family of conditions in which streptococcal infection is thought to provoke neurological symptoms. The best established of these is Sydenham chorea, a movement disorder that can follow rheumatic fever. PANDAS is best understood as a related but distinct presentation, defined by its psychiatric and behavioural features.

Why the Brain Is the Target

The brain is normally protected from circulating antibodies by the blood-brain barrier, a selective interface between the bloodstream and the central nervous system. Two features make the PANDAS hypothesis biologically plausible.

Cross-reactive antibodies. Antibodies raised against streptococcal cell wall components can bind to proteins found on neurons, particularly in regions of the brain that help regulate movement and repetitive behaviour.
Inflammation in deep brain structures. The basal ganglia — a cluster of nuclei involved in motor control, habit formation and the gating of unwanted thoughts and actions — is the region most often implicated.

Imaging studies have reported enlargement of the basal ganglia and other structures during acute episodes in some children, with changes that partially resolve as symptoms improve. These findings are not universal, and they have not yet produced a diagnostic test. The brain involvement in PANDAS is therefore best described as an active area of research rather than a settled measurement.

Recognising the Pattern

PANDAS is defined by a characteristic clinical pattern rather than by a single laboratory result. The features most often used to describe it include:

Sudden onset. Symptoms typically appear abruptly, often overnight or over one to two days, rather than gradually.
Obsessive-compulsive symptoms or tics. These are the hallmark features, and they may appear together.
An association with streptococcal infection. Onset or worsening is linked in time to a documented or suspected group A streptococcal infection.
An episodic course. Symptoms flare and remit, with relapses often following new infections or other immune triggers.
Accompanying neurological and behavioural changes. These may include emotional lability, separation anxiety, irritability, deterioration in handwriting, frequent urination, sleep disturbance, and sensitivity to sensations such as touch or sound.
Young age at onset. The pattern is generally described in prepubertal children, most commonly between about three and twelve years of age.

The abruptness of onset is often what most alarms families. A child who was functioning well can develop intense rituals, disabling fears or involuntary movements within days.

Overlap with PANS

Because many children present with the same sudden neuropsychiatric picture without a clear streptococcal link, clinicians and researchers increasingly use the broader term PANS — Pediatric Acute-onset Neuropsychiatric Syndrome. PANS is defined by abrupt onset of obsessive-compulsive symptoms or severely restricted eating, together with additional neuropsychiatric symptoms, without requiring a specific infectious trigger.

PANDAS can be thought of as the streptococcus-associated subset of PANS. The distinction matters clinically, because it shapes what infections or other triggers are looked for, but the day-to-day management of the two groups overlaps considerably.

How the Diagnosis Is Made

There is no blood test, scan or swab that confirms PANDAS. Diagnosis rests on a careful clinical assessment that establishes the characteristic pattern and rules out other explanations.

Evaluation usually involves:

A detailed history of when symptoms began, how they evolved, and whether they followed an infection.
A thorough physical and neurological examination, including assessment of movements and tics.
Evidence of a recent group A streptococcal infection, such as a throat swab, a rapid antigen test, or rising antibody titres. A positive result supports the association but does not by itself make the diagnosis, since many children carry the bacterium without symptoms.
Consideration of alternative conditions, including other autoimmune and inflammatory brain disorders, tic disorders, obsessive-compulsive disorder without an infectious trigger, and metabolic or genetic conditions.

Because the presentation is easily mistaken for a primary psychiatric disorder, children are often assessed by more than one specialty before the pattern is recognised.

Treatment Approaches

Management is generally organised around several strands, and evidence for each varies in strength.

Treating the infection

When an active streptococcal infection is present, it is treated with antibiotics in the usual way. Some clinicians also use prophylactic antibiotics in children with repeated flares tied to repeated infections, though the evidence for this practice is limited and it carries the usual risks of long-term antibiotic use.

Treating the psychiatric and behavioural symptoms

Obsessive-compulsive symptoms and tics are commonly managed with the same approaches used in children without an infectious trigger. These include cognitive behavioural therapy with exposure and response prevention, and, where appropriate, medication such as selective serotonin reuptake inhibitors. These treatments address the symptoms whether or not the underlying mechanism is autoimmune.

Immune-based treatments

For children with severe, disabling symptoms that do not respond to standard care, some specialists use immune-modulating treatments. These have included corticosteroids, intravenous immunoglobulin, and therapeutic plasma exchange. These interventions are not without risk and are generally reserved for selected cases, ideally within research or specialist settings. Evidence for their effectiveness remains limited and mixed.

Support for the child and family

Because episodes can be abrupt and frightening, education, school liaison and psychological support for the whole family form an important part of care. Symptoms that fluctuate can place considerable strain on a household, and understanding the pattern helps families respond calmly.

The Scientific Debate

PANDAS is a recognised clinical concept in some settings and a contested one in others. Key areas of disagreement include:

Diagnostic boundaries. The criteria rely on clinical judgement, which makes consistent identification across clinics difficult.
Mechanism. Molecular mimicry is well documented in Sydenham chorea, but proving the same process in children with obsessive-compulsive symptoms and tics has been harder.
Biomarkers. No reliable laboratory marker distinguishes PANDAS from other childhood-onset neuropsychiatric conditions.
Treatment evidence. Trials of immune therapies have been small and have produced inconsistent results, so firm conclusions are difficult to draw.

Much of the disagreement stems from the difficulty of studying a condition defined by a clinical pattern rather than by a measurable biological signature. Larger, better controlled studies are needed before the field can settle these questions.

Where Research Is Heading

Current work is focused on finding objective markers that could confirm the diagnosis, track disease activity and predict relapses. Areas under investigation include patterns of antibodies that cross-react with brain tissue, imaging of the basal ganglia, markers of inflammation in blood and cerebrospinal fluid, and genetic factors that may influence susceptibility to post-infectious autoimmunity.

A clearer biological signature would also make it possible to test treatments in a targeted way, so that immune-based therapy could be offered to the children most likely to benefit and avoided in those unlikely to respond.

Key Points for Families and Clinicians

PANDAS describes the sudden onset of obsessive-compulsive symptoms or tics in children, linked in time to group A streptococcal infection.
The leading explanation is an autoimmune disease process in which antibodies against the bacterium cross-react with the brain, particularly the basal ganglia.
Diagnosis is clinical. There is no confirmatory test, and other conditions must be excluded.
Treatment usually combines standard care for obsessive-compulsive symptoms and tics with antibiotic treatment of active infection.
Immune-modulating therapies are used in selected severe cases, but the evidence base remains limited.
The condition is the subject of ongoing scientific debate, and families should expect that opinions among clinicians may differ.

Anyone concerned that a child may have PANDAS or PANS should seek assessment from a qualified medical professional, ideally one with experience in childhood neuropsychiatric disorders. General information about related research is available from the National Institute of Mental Health.